Abbott announced positive long-term results for the company's innovative Absorb Bioresorbable Vascular Scaffold (BVS). Three-year results from 101 patients in the second stage of the ABSORB trial were presented at the 62nd Annual Scientific Session of the American College of Cardiology (ACC) in San Francisco. Absorb is commercially available in Europe as well as other international markets and is an investigational device in the United States.

March 14, 2013 — Researchers from Perelman School of Medicine at the University of Pennsylvania are showing in a small study that while niacin increased measured levels of HDL-C, it did not improve the functionality of HDL. This may provide an explanation for the failure of niacin to further reduce cardiovascular risk. These study results were reported at the 62nd annual scientific session of the American College of Cardiology in San Francisco.

March 14, 2013 — Lantheus Medical Imaging Inc. announced the U.S. Food and Drug Administration (FDA) has granted approval of a supplemental new drug application (sNDA) that allows Jubilant HollisterStier (JHS) to be a new manufacturing site for its ultrasound imaging agent, Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension.


March 13, 2013 — St. Jude Medical Inc. announced the first patient implant in a new pivotal trial evaluating the company’s Amplatzer cardiac plug (ACP) for the prevention of stroke.

March 13, 2013 — CircuLite Inc. announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) for an investigational device exemption (IDE) for its lead product, the Synergy circulatory support system, a minimally invasive device designed to reverse the symptoms of heart failure in ambulatory chronic heart failure patients.

Mummies Egypt Atherosclerosis CT Systems
PAD, mummy
Aortic valve stenosis in a 3,000 year old Egyptian mummy.

http://www.thelancet.comAtherosclerosis is usually considered to be related to contemporary risk factors such as smoking, obesity and lack of exercise. However, researchers suggest that high prevalence of atherosclerosis in pre-modern humans may support the possibility of a more basic human predisposition to the disease.
Contrast Agents Mayo Clinic Clinical Study Kidney Injury

Many physicians have long believed that the use of intravenous contrast agents for computed tomography (CT) scans can cause acute kidney injury. New Mayo Clinic research questions the strength of the causal link between the two. The findings from two tandem studies are published online in the journal Radiology.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now